Subjects at risk of familial Alzheimer's disease (FAD) offer the best chance to observe the earliest effects of the disease and would be candidates for presymptomatic trials. Currently there is relatively little longitudinal data available on subjects in the earliest stages of disease. Here, we analyze the atrophy rates of key structures in a local longitudinal FAD cohort which has been followed
... [Show full abstract] for up to two decades.